EEF2
Elongation factor 2
Protein Summary
Catalyzes the GTP-dependent ribosomal translocation step during translation elongation. During this step, the ribosome changes from the pre-translocational (PRE) to the post-translocational (POST) state as the newly formed A-site-bound peptidyl-tRNA and P-site-bound deacylated tRNA move to the P and E sites, respectively. Catalyzes the coordinated movement of the two tRNA molecules, the mRNA and conformational changes in the ribosome. This gene encodes a member of the GTP-binding translation elongation factor family. This protein is an essential factor for protein synthesis. It promotes the GTP-dependent translocation of the nascent protein chain from the A-site to the P-site of the ribosome. This protein is completely inactivated by EF-2 kinase phosporylation. [provided by RefSeq, Jul 2008]
- ENST00000309311
- ENSP00000307940
- ENSG00000167658
- EF2
- EF2
- EF-2
- EEF-2
- SCA26
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
disease perturbation | 1 | ||
interacting protein | 1 | ||
protein domain | 1 | ||
kinase perturbation | 0.98 | ||
molecular function | 0.98 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 1844.96 (req: < 5)
Gene RIFs: 40 (req: <= 3)
Antibodies: 493 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 1844.96 (req: >= 5)
Gene RIFs: 40 (req: > 3)
Antibodies: 493 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 26
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 1
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0